| 21.4104 -0.43 (-1.97%) | 10-22 15:06 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 29.03  |
1-year : | 32.22 |
| Resists | First : | 24.86 |
Second : | 27.59 |
| Pivot price | 21.98 |
|||
| Supports | First : | 20.45 | Second : | 17.01 |
| MAs | MA(5) : | 21.39  |
MA(20) : | 22.31 |
| MA(100) : | 29.58 |
MA(250) : | 26.34 |
|
| MACD | MACD : | -1.7 |
Signal : | -2 |
| %K %D | K(14,3) : | 40 |
D(3) : | 31.7 |
| RSI | RSI(14): 35.1 |
|||
| 52-week | High : | 39.52 | Low : | 15.52 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TECX ] has closed above bottom band by 35.4%. Bollinger Bands are 57% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 22.32 - 22.4 | 22.4 - 22.49 |
| Low: | 21.31 - 21.41 | 21.41 - 21.51 |
| Close: | 21.68 - 21.83 | 21.83 - 21.99 |
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
Wed, 14 Oct 2026
Tectonic Therapeutic, Inc. (TECX) Presents at CureHHT 16thHHT International Scientific Conference - Slideshow - Seeking Alpha
Sat, 10 Oct 2026
TECX: Tectonic Therapeutic Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Wed, 30 Sep 2026
493 shares are proposed for sale by officer Peter McNamara at Tectonic Therapeutic (TECX). - Stock Titan
Wed, 30 Sep 2026
Oppenheimer reiterates Tectonic Therapeutics stock rating on TX2100 data - Investing.com
Wed, 09 Sep 2026
Tectonic Therapeutic (TECX) Clears Two Trial Hurdles With Cash To Spare - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 20 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 37.5 (%) |
| Held by Institutions | 71.7 (%) |
| Shares Short | 2,220 (K) |
| Shares Short P.Month | 1,940 (K) |
| EPS | -4.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.64 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.3 % |
| Return on Equity (ttm) | -33.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -72 (M) |
| Levered Free Cash Flow | -47 (M) |
| PE Ratio | -4.71 |
| PEG Ratio | 0 |
| Price to Book value | 1.84 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|